



**Food and Drug Administration  
OFFICE OF CRIMINAL INVESTIGATIONS  
REPORT OF INVESTIGATION**

**REPORTING OFFICE:** San Francisco Resident Office

**DOCUMENT NUMBER:** 235969

**CASE NUMBER:** 2010-SFC-735-0280

**RELATED CASE NUMBER:** (b) (7)(E)

**TYPE OF CASE:** 735.100, DIETARY SUPPLEMENTS - CDER

**CASE TITLE:** PRIMORDIAL PERFORMANCE

**CASE AGENT:** (b) (7)(F)

**INVESTIGATION MADE AT:** Oakland, CA and Portland, OR

**INVESTIGATION MADE BY:** Special Agent (b) (7)(F)

**REPORTING PERIOD:** **FROM:** 01/06/2015 **TO:** 04/04/2015

**STATUS OF CASE:** Continued

**SYNOPSIS:** Met with AUSA to discuss investigation, interviewed witness, received results of FCC analysis.

\*\*\*\*\*  
**RESTRICTED INFORMATION**

This report is furnished on an official need-to-know basis and must be protected from dissemination which might compromise the best interests of the Food and Drug Administration, Office of Criminal Investigations. This report shall not be released in response to a Freedom of Information Act or Privacy Act request or disseminated to other parties without prior consultation with the FDA Office of Criminal Investigations.

**UNAUTHORIZED RELEASE MAY RESULT IN CRIMINAL PROSECUTION**  
\*\*\*\*\*

**REPORT SUBMITTED BY:** Electronically submitted by (b) (7)(F) DATE: 04/07/2015  
 (b) (7)(F) SPECIAL AGENT

**REPORT APPROVED BY:** Electronically approved by STEPHEN JACKSON DATE: 04/07/2015  
 STEPHEN JACKSON, RESIDENT AGENT IN CHARGE

**DISTRIBUTION:** ORIG: SFC

## 1. INTRODUCTION:

This case originated after the February 8, 2010, receipt of information from the United States Anti-Doping Agency (USADA) about an email solicitation from PRIMORDIAL PERFORMANCE on the sale of a new product called Superdrone. The email indicates that PRIMORDIAL PERFORMANCE's Superdrone is a "Superdrol-clone" and contains the designer anabolic steroid methyldrostanolone. Superdrol (aka methyldrostanolone, aka methasteron) is a designer anabolic steroid (b) (7)(E)

(b) (7)(E)

Reference is made to the Report of Investigation for the period October 16, 2014 through January 5, 2015.

## 2. DETAILS OF INVESTIGATION:

On February 3, 2015, SA (b) (7) (F) met with AUSA Parrella to discuss the investigation.

Continuing on the same day, SA (b) (7) (F) emailed R.D. Satzger, Ph.D., Director of the FCC, and requested information pertaining to "PRIMORDIAL PERFORMANCE AndroMass" that was submitted to the FCC for analysis on June 10, 2011, on CIE number 172224, by SA (b) (7)(F).

On February 4, 2015, SA (b) (7) (F) emailed Johnathan Litzau, Supervisory Chemist for the FCC, and requested information pertaining to "PRIMORDIAL PERFORMANCE AndroMass" that was submitted to the FCC for analysis on June 10, 2011, on CIE number 172224, by SA (b) (7)(F).

On February 5, 2015, two items from CIE number 185188 were sent to the FCC for analysis (See evidence section for details).

Continuing on the same day, SA (b) (7) (F) spoke with Litzau via telephone. SA (b) (7) (F) asked Litzau about FACTS number 794376 which summarized the FCC findings for items submitted for analysis on CIE number 185208 by SA (b) (7)(F). More specifically, SA (b) (7) (F) asked about "Item 30- portions of powder" which the FCC identified as containing "Three unknown steroids". (b) (7) (5)

SA (b) (7) (F) also asked Litzau about information pertaining to "PRIMORDIAL PERFORMANCE AndroMass" that was submitted to the FCC for analysis on June 10, 2011, on CIE number 172224 by SA (b) (7)(F). Litzau stated he would have one of his employees locate the report and would provide it via email. SA (b) (7) (F) explained he had submitted a request for analysis of two items, "ANDROmass" and "ANDRObulk" on CIE number 185188. SA (b) (7) (F) requested that the screening of controlled substances, anabolic steroids, and toxins be expedited per the request of the AUSA. Litzau stated they should be able to have the preliminary results of the screening within one to two days from the receipt of the items. SA (b) (7) (F) also asked Litzau about "Item 2- Drum 1" and "Item 3- Drum 2" that were submitted for FCC analysis on CIE number 185389. SA (b) (7) (F) stated he

knew the preliminary analysis had been completed on most of the products found within in the drum and wanted to confirm that no controlled substances were found. (b) (5)

Finally, SA (b) (7) (F) explained that he had an upcoming meeting with the AUSA and requested Litzau to attend via conference call. Litzau agreed to this request.

Continuing on the same day, SA (b) (7) (F) interviewed (b) (6), (b) (7)(C) was previously interviewed by SA (b) (7)(F) and SA (b) (7)(F) on February 15, 2011. This interview was documented in an MOI, (b) (7)(E) SA Roy asked (b) (6), (b) (7)(C)

[Redacted]

(b) (7)(F), (b) (7)(E)

Continuing on the same day, SA (b) (7) (F) received an FCC analysis report (FACTS 697184) for the "AndroMass", inventoried on CIE number 172224, which was received by the lab on June 10, 2011. (b) (5)

[Redacted]

(b) (7) (F)

b) (7) (F)

(b) (5)

[Redacted]

On February 19, 2015, SA (b) (7) (F) met with AUSA Parrella to discuss the investigation.

On March 2, 2015, SA <sup>(b) (7)</sup><sub>(F)</sub> submitted a request to SOM Robert Pursel to organize a conference call with CFSAN to discuss the substances identified by the FCC in various products sold by PRIMORDIAL PERFORMANCE.

### 3. JUDICIAL ACTION:

None this reporting period

### 4. DISPOSITION OF EVIDENCE, CONTRABAND, AND PERSONAL PROPERTY:

On January 5, 2015, the following evidence, inventoried on CIE # 185188 was sent to the FCC for analysis:

Item 1- "Black box labeled in part, "Primordial Performance ANDROmass, 168 Softgels, Dietary Supplement"

Item 2- "Black box labeled in part, "Primordial Performance ANDRObulk, 168 Softgels, Dietary Supplement"

### 5. STATUS OF INVESTIGATION:

Continued.

### 6. SUSPECTS/DEFENDANTS/OTHER:

PRIMORDIAL PERFORMANCE

ERIC POTRATZ

(b) (6), (b) (7)(C)

WWW.PRIMORDIALPERFORMANCE.COM

(b) (6), (b) (7)(C)

### 7. ATTACHMENTS:

None.